Regeneron: Is Eylea At Risk?
June 21, 2017 at 11:59 AM EDT
An experimental eye drug from Novartis could rival Regeneron's blockbuster drug Eylea. What does that mean for Regeneron's stock price?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|